1. Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F (2017) Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther 34:560–575
2. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S (2008) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 4:CD5031
3. Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 9:CD5031
4. Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 10:CD4147
5. Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A (2017) Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol 7:119–134.
https://doi.org/10.1177/2045125316681984